Morka Benti, Belay Keno Firezer, Gebre Dejene Seyoum, Fikadu Worku, Tiruneh Gemechu, Golja Eba Abdisa, Ewunetu Adisu
Horro Guduru Wallaga Zone Health Department, Shambu, Ethiopia.
School of Public Health, Institute of Health Science, Wallaga University, Nekemte, Ethiopia.
Front Public Health. 2025 Apr 16;13:1565573. doi: 10.3389/fpubh.2025.1565573. eCollection 2025.
People with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) continue to die at substantial rates, even in our nation of Ethiopia, despite receiving antiretroviral medication. Limited evidence is available regarding these individuals' time to death and its predictors. Therefore, this study aimed to evaluate time to death and its predictors among HIV/AIDS patients receiving antiretroviral therapy (ART) in this study area.
The objective of the study was to assess time to death and its predictors among HIV patients receiving ART in public facilities of the Horro Guduru Wallaga (HGW) zone, Western Ethiopia, 2024.
A facility-based retrospective study was conducted involving 538 HIV-positive patients on anti-retroviral therapy. A simple random sampling method was used to select a sample from patient registrations between October 2018 and October 2023. Data were entered into EpiData version 3.1 and exported to STATA version 14. The Kaplan-Meier curve was used to estimate the survival probability after ART initiation. The Cox regression model was used to identify independent predictors of death. Significantly associated variables were reported with a -value of less than 0.05 and the adjusted hazard ratio (AHR) with a 95% confidence interval.
Among the 538 study participants included in the final analysis, 42 (8%) individuals died. The finding of this study revealed that the incidence rate of HIV-related death was 2.81 deaths per 1,000 person-months. Diarrhea (AHR = 4.54; 95% CI 1.85-11.13), failure to take TB prophylaxis (AHR = 5.61; 95%CI: 2.25, 14.03), non-utilization of condoms (AHR = 2.62; 95% CI: 1.13, 6.08), and WHO clinical stages III and IV (AHR = 7.02; 95%CI: 3.11, 11.84) were identified as predictors of death among the patients.
The time to death among HIV patients on ART in this study area was higher compared to the national HIV-related death report. A history of diarrhea, failure to adhere to tuberculosis prophylaxis, non-utilization of condoms, and HIV clinical stages III and IV were found to be predictors of time to death related to HIV. Therefore, it is important to promote behavioral changes, such as condom utilization, adherence to TB prophylaxis, and effective treatment of comorbid infections, to improve the lifespan of HIV patients.
即使在我们埃塞俄比亚这个国家,感染人类免疫缺陷病毒(HIV)/获得性免疫缺陷综合征(AIDS)的人在接受抗逆转录病毒药物治疗的情况下,仍有相当高的死亡率。关于这些人的死亡时间及其预测因素的证据有限。因此,本研究旨在评估该研究地区接受抗逆转录病毒治疗(ART)的HIV/AIDS患者的死亡时间及其预测因素。
本研究的目的是评估2024年埃塞俄比亚西部霍罗古杜鲁瓦拉加(HGW)地区公共设施中接受ART的HIV患者的死亡时间及其预测因素。
进行了一项基于机构的回顾性研究,涉及538名接受抗逆转录病毒治疗的HIV阳性患者。采用简单随机抽样方法从2018年10月至2023年10月期间的患者登记记录中选取样本。数据录入EpiData 3.1版本,并导出到STATA 14版本。使用Kaplan-Meier曲线估计开始ART后的生存概率。使用Cox回归模型确定死亡的独立预测因素。报告具有显著相关性的变量时,P值小于0.05,并给出调整后的风险比(AHR)及其95%置信区间。
在最终分析纳入的538名研究参与者中,42人(8%)死亡。本研究结果显示,HIV相关死亡的发生率为每1000人月2.81例死亡。腹泻(AHR = 4.54;95% CI 1.85 - 11.13)、未采取结核病预防措施(AHR = 5.61;95%CI:2.25,14.03)、未使用避孕套(AHR = 2.62;95% CI:1.13,6.08)以及世界卫生组织临床分期III和IV期(AHR = 7.02;95%CI:3.11,11.84)被确定为患者死亡的预测因素。
与全国HIV相关死亡报告相比,该研究地区接受ART的HIV患者的死亡时间更高。腹泻病史、未坚持结核病预防、未使用避孕套以及HIV临床分期III和IV期被发现是与HIV相关的死亡时间的预测因素。因此,促进行为改变,如使用避孕套、坚持结核病预防以及有效治疗合并感染,对于提高HIV患者的寿命很重要。